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Sustained viral response (SVR) rates for direct- acting antiviral (DAA) therapy for 
hepatitis C virus (HCV) infection routinely exceed 95%. However, a small number 
of patients require retreatment. Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/
VOX) is a potent DAA combination primarily used for the retreatment of patients 
who failed by DAA therapies. Here we evaluate retreatment outcomes and the ef-
fects of resistance- associated substitutions (RAS) in a real- world cohort, including a 
large number of genotype (GT)3 infected patients. 144 patients from the UK were re-
treated with SOF/VEL/VOX following virologic failure with first- line DAA treatment 
regimens. Full- length HCV genome sequencing was performed prior to retreatment 
with SOF/VEL/VOX. HCV subtypes were assigned and RAS relevant to each geno-
type were identified. GT1a and GT3a each made up 38% (GT1a n = 55, GT3a n = 54) 
of the cohort. 40% (n = 58) of patients had liver cirrhosis of whom 7% (n = 4) were 
decompensated, 10% (n = 14) had hepatocellular carcinoma (HCC) and 8% (n = 12) 
had received a liver transplant prior to retreatment. The overall retreatment SVR12 
rate was 90% (129/144). On univariate analysis, GT3 infection (50/62; SVR = 81%, 
p = .009), cirrhosis (47/58; SVR = 81%, p = .01) and prior treatment with SOF/VEL 
(12/17; SVR = 71%, p = .02) or SOF+DCV (14/19; SVR = 74%, p = .012) were signifi-
cantly associated with retreatment failure, but existence of pre- retreatment RAS was 
not when viral genotype was taken into account. Retreatment with SOF/VEL/VOX is 
very successful for non- GT3- infected patients. However, for GT3- infected patients, 
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1  |  INTRODUC TION
Sustained virological response (SVR) rates for patients chronically 
infected with hepatitis C virus (HCV) and treated with direct- acting 
antiviral (DAA) therapies in clinical trials and real- world cohorts are 
often >95%.1- 3 Treatment failure is associated with multiple host and 
viral factors including advanced fibrosis or cirrhosis, HCV subtype4- 6 
and the presence of resistance- associated substitutions (RAS) in 
HCV- encoded proteins that are targeted by DAA.7 This leaves a 
small percentage of HCV- infected patients who have been failed by 
first- line therapies and are therefore by definition “difficult to treat”. 
For patients who have been failed by pan- genotypic regimens such 
as SOF/VEL and glecaprevir and pibrentasvir, (GLE/PIB) retreatment 
options are limited. Currently the European Association for the 
Study of the Liver (EASL) and American Association for the Study 
of Liver Disease (AASLD), recommend a combination of sofosbuvir, 
velpatasvir and voxilaprevir (SOF/VEL/VOX) for these patients.8,9
Retreatment of patients previously failed by predominantly first- 
generation NS5A inhibitor- containing DAA therapy with SOF/VEL/
VOX has been evaluated in both the POLARIS- 1 and POLARIS- 4 
phase- II and III studies.10 In these studies, SOF/VEL/VOX showed 
a very high SVR rate in GT1- infected patients (222/228; 97% SVR); 
however, a slightly lower SVR rate was observed in GT3 patients 
(126/132; 95% SVR). In addition, a number of studies have evaluated 
the observed real- world outcomes of SOF/VEL/VOX retreatment. 
The largest cohort (n = 573) reported by Belperio et al,11 showed 
lower SVR rates than in the POLARIS 1 and 4 studies for all geno-
types (GT1: 429/473; 91% SVR, GT2: 18/20; 90% SVR, GT3: 42/46; 
91% SVR, GT4: 12/12; 100% SVR). This study also showed that the 
SVR rate for those who had received SOF/VEL as first- line therapy, 
was reduced for GTs 1– 3 (GT1: 15/19; 79% SVR, GT2: 13/15; 87% 
SVR, GT3: 11/13; 85% SVR). In an Italian cohort,12 the SVR rate was 
95% (162/169) with cirrhosis and hepatocellular carcinoma (HCC) 
being associated with treatment failure, however, there was no sig-
nificant difference between the SVR rates of patients with different 
genotypes (GT1: 98/101; 97% SVR, GT2: 17/17; 100% SVR, GT3: 
33/36; 91% SVR, GT4: 14/15; 93% SVR). Finally, Llaneras et al13 re-
ported an overall SVR rate of 95% (128/135) with 100% in patients 
with GT1 (82/82) and GT2 (7/7) infection, 80% (24/30) in GT3 and 
93% (13/14) in GT4. SVR rates were significantly lower in patients 
with cirrhosis (89%, p = .05), or those with GT3 infection (80%, 
p < .001), whilst patients with GT3 infection and cirrhosis had the 
lowest SVR rate (69%).
Despite these studies there remains limited data on SOF/
VEL/VOX retreatment from the real- world setting, particularly for 
patients with GT3 infection following unsuccessful therapy with 
pan- genotypic DAA regimens. These data are required to inform op-
timal retreatment strategies. In this paper, we report the outcomes 
of 144 patients failed by first- line DAA therapy and retreated with 
SOF/VEL/VOX. We then analyse the effect of clinical characteris-
tics and RAS on SOF/VEL/VOX retreatment.
2  |  METHODS
2.1  |  Patients and samples
This study included 215 individuals from across England who did 
not achieve SVR with previous interferon- free DAA treatment. 
Blood samples were taken prior to retreatment and samples sent 
to Oxford and Glasgow for HCV whole- genome sequencing (WGS). 
Clinical, demographical and treatment outcome data were collected 
from patients, who were enrolled in HCV Research UK (n = 37), fol-
lowing informed consent and ethical approval.14 For patients not 
enrolled in HCV Research UK, whole- genome HCV sequences and 
anonymised clinical data were provided by Public Health England 
(PHE), collected as part of the Virus Reference Department's HCV 
antiviral resistance testing service. This provides a clinical service 
for National Health Service Trusts, which send patients’ blood sam-
ples for HCV genotyping and resistance testing by WGS and receive 
results in real time to inform clinical management. Approval for the 
use of data from this service was granted under Regulation 3 of the 
Health Service (Control of Patient Information) Regulations 2002. 
For retreatment, SVR has defined a minimum of 12 weeks after the 
end of treatment.
This project has been supported by the Hepatitis C Trust an or-
ganisation which campaigns for issues affecting patients with HCV 
in the UK. A patient representative was present at all STOP- HCV 
steering group committee meetings where the plans for this study 
were discussed in detail with direct patient involvement in the plan-
ning at all stages. In addition, both HCV Research UK and Public 
Health England have a Patient and Public Involvement Strategy and 
engage with patients and the public about how the data collected 
by them is used.
2.2  |  Whole genome sequencing of HCV
Whole HCV genome sequencing was conducted at three sites to 
define HCV subtype and identify RAS: (i) The MRC- University of 
particularly those with cirrhosis and failed by initial SOF/VEL treatment, SVR rates 
were significantly lower and alternative retreatment regimens should be considered.
K E Y W O R D S
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Glasgow Centre for Virus Research (CVR), (ii) The Peter Medawar 
Building for Pathogen Research, University of Oxford, and (iii) The 
Virus Reference Department, National Infection Service, Public 
Health England. These sites have previously collaborated to ensure 
uniform standards for HCV sequencing.15 Briefly, RNA was isolated 
from patient plasma samples and reverse transcribed to produce 
cDNA. An Illumina sequencing library was generated and enriched 
for HCV viral sequences using specific oligonucleotide probes. 
Illumina sequencing reads were then processed and mapped to the 
closest HCV reference genome. Precise details of how the sequenc-
ing was performed at each site are described in the supplementary 
materials.
2.3  |  Resistance- associated substitution calling 
using HCV- GLUE
HCV subtypes were assigned and NS3, NS5A and NS5B RAS rel-
evant to each genotype were identified (15% of reads cut off) using 
HCV- GLUE and RAS definitions provided by PHE16 (Supplementary 
Table 3). A RAS was considered relevant if there is in- vitro evi-
dence of a >50 Fold change in EC50 and/or in- vivo evidence that 
the RAS is treatment emergent or associated with treatment failure. 
HCV- GLUE is a resource created as part of the STOP- HCV consor-
tium based on the GLUE (Genes Linked by Underlying Evolution) 
platform.17 HCV- GLUE uses the ICCT HCV reference sequences and 
collates publicly available HCV sequences, to construct phylogenies 
using RAxML to assign sequences to HCV clades. It also contains a 
database of HCV RAS created by PHE16 and this is used to identify 
RAS relevant to the HCV genotype and subtype.18
2.4  |  Statistical analysis
All statistical analysis was performed using custom code and R ver-
sion 3.6.2. Logistic regression was used for the analysis of associa-
tion between categorical variables.
3  |  RESULTS
3.1  |  Baseline characteristics of patients
Outcomes were available for 144 patients who were retreated with 
SOF/VEL/VOX. The mean age was 56 years (49– 63 IQR) with 84% 
(n = 121) of the cohort being male. Overall, 40% (n = 58) had cir-
rhosis, with 7% (n = 4) decompensated. Of 10% (n = 14) had HCC 
and 8% (n = 12) had received a liver transplant prior to retreatment 
(Table 1). The median time from the end of previous treatment to 
pre- retreatment sequencing analysis was 13 months (2– 32 Range). 
TA B L E  1  Clinical characteristics of 144 patients prior to retreatment with SOF/VEL/VOX split by genotype
GT1 (n = 66) GT2 (n = 3) GT3 (n = 62) GT4 (n = 10) GT6 (n = 3)
Demographics
Median age (IQR), years 54 (48- 60) 64 (56- 67) 57 (51- 62) 62 (57- 75) 27 (27- 44)
Sex: Male 86% (56/65)a  67% (2/3) 85% (53/62) 70% (7/10) 100% (3/3)
Liver disease State
Cirrhosis 24% (16/66) 67% (2/3) 60% (37/62) 30% (3/10) 0% (0/3)
Decompensated cirrhosis 0% (0/16) 0% (0/2) 11% (4/37) 0% (0/3) 0% (0/0)
Hepatocellular carcinoma 9% (6/66) 0% (0/3) 13% (8/62) 0% (0/10) 0% (0/3)
Prior liver transplant 3% (2/66) 33% (1/3) 15% (9/62) 0% (0/10) 0% (0/3)
Mean baseline viral load, 
log10 IU/ml (IQR)
6.6 (6.0- 6.7) 6.0 (5.9- 6.2) 6.4 (5.5- 6.5) 7.1 (5.6- 6.7) 6.2 (6.0- 6.3)
Previous DAA treatment regimenb 
SOF/LDV 38% (25/66) - 10% (6/62) 40% (4/10) - 
SOF/VEL 2% (1/66) - 26% (16/62) - - 
GLE/PIB 2% (1/66) - 24% (15/62) - 100% (3/3)
SOF + DCV - - 31% (19/62) - - 
EBR/GZR 15% (10/66) - - 20% (2/10) - 
OBV/PTVr +/- DAS 32% (21/66) - 2% (1/62) 30% (3/10) - 
SOF 2% (1/66) 100% (3/3) 6% (4/62) - - 
Unknown 11% (7/66) - 2% (1/62) 10% (1/10) - 
Abbreviations: DAS, Dasabuvir; DCV, Daclatasvir; EBR, Elbasvir; GLE, Glecaprevir; GZR, Grazoprevir; LDV, Ledipasvir; OBV, Ombitasvir; PIB, 
Pibrentasvir; PTV, Paritaprevir; r, Ritonavir; SOF, Sofosbuvir; VEL, Velpatasvir.
aData missing for one patient.
bFull breakdown of previous treatment regimens including ribavirin and interferon use are in Supplementary Table 1.
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GT1a and GT3a were the two most common subtypes, each making 
up 38% (GT1a n = 55, GT3a n = 54) of the cohort, 17 other subtypes 
were identified from genotypes 1, 2, 3, 4 and 6, with GT1b, GT4r and 
GT3b making up 6% (n = 9), 4% (n = 6), and 3% (n = 5) of the cohort 
respectively (Figure 1).
3.2  |  Effectiveness of retreatment with SOF/VEL/
VOX
The overall SVR12 rate for patients retreated with SOF/VEL/VOX 
was 91% (n = 129) (Figure 2). The majority of patients who did 
not achieve an SVR (n = 15) experienced a post- treatment relapse 
(n = 10). One patient experienced an on- treatment breakthrough 
(patient's HCV RNA was undetectable during treatment and then 
became detectable again during treatment.) and two were non- 
responders (patients who never achieve undetectable HCV RNA). 
Relapse/breakthrough/non- response was not reported by the 
treating clinician for the remaining two patients. Poor adherence to 
retreatment was not reported for any of the patients who did not 
achieve an SVR.
Evaluating the factors associated with outcome using univari-
able logistic regression, GT3 infection (52/64; SVR = 81%, p = .009) 
and cirrhosis (47/58; SVR = 81%, p = .01) were both significantly 
associated with treatment outcome (Figure 3). Patients whose ini-
tial regimen was either SOF/VEL or SOF +DAC were also less likely 
to achieve SVR on retreatment (12/17, 71% = 0.02 and 14/19, 74%, 
p = .012 respectively). Patients with GT3 infection, cirrhosis and 
prior treatment with SOF/VEL had the lowest SVR rate of 42% (3/7). 
However, one of these patients only received 4 weeks of SOF/VEL/
VOX (Supplementary Table 2). Multivariable analysis using logistic 
regression with SVR as the response variable and GT, presence/
absence of cirrhosis and previous treatment regimen included as 
explanatory variables, revealed that prior treatment with SOF/VEL 
had the largest effect on SVR and remained the only variable signifi-
cantly associated with outcome (p = .03) (Supplementary Figure 1). 
However, with the exception of one GT1 patient previously treated 
with SOF/VEL, all patients with prior SOF/VEL or SOF +DCV treat-
ment had GT3 infection which confounded this result (Table 1). 
When GT3- infected patients were analysed separately, cirrhosis and 
prior treatment regimen were no longer significantly associated with 
outcome, in both the univariable and multivariable analysis.
3.3  |  Effect of resistance- associated substitutions 
on retreatment outcome
Among the 144 patients retreated with SOF/VEL/VOX and with 
available outcomes, 70% (101/144) had detectable RAS prior to re-
treatment. 16% had NS3 inhibitor RAS, 51% NS5A inhibitor RAS and 
34% SOF RAS. However, the majority of SOF RAS were detected in 
GT3a sequences (Supplementary Figure 2). Of the viral sequences 
in 15 patients failed by SOF/VEL/VOX retreatment, 12/15 (80%) 
had detectable RAS prior to retreatment compared to 89/129 (68%) 
in those subsequently achieving SVR. However, despite the high 
prevalence of RAS, the presence of a RAS in a particular protein or 
F I G U R E  1  HCV Subtypes of the 144 patients failed by first- line DAA therapy and retreated with SOF/VEL/VOX. The percentage 
prevalence of each subtype is shown broken down by HCV genotype. Sequences which could not be assigned to subtypes have been 
labelled with the appropriate genotype
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combination of proteins was not significantly associated with the 
outcome (Table 2). When each RAS (Full list in Table 3) was consid-
ered independently using logistic regression, A30K and Y93H RAS in 
NS5A were associated with retreatment failure in the whole cohort 
(A30K p = .02, Y93H p = .01) (Table 3). The A30K RAS is unique 
to GT3a (it is wild- type in GT3b) and the Y93H substitution was 
much more common in GT3 patients compared to other genotypes 
(Supplementary Figure 2). When the analysis is limited to GT3 pa-
tients, the SVR rates for patients with these RAS were still reduced 
(for A30K SVR, 71% and Y93H SVR, 78%) but this was no longer 
statistically significant (A30K p = .2, Y93H p = .3). In addition, when 
the genotype is added as a cofactor to the logistic regression Y93H is 
no longer associated with the outcome. Whilst individually the A30K 
and Y93H RAS are common, the combination of A30K + Y93H is 
found rarely and is not associated with treatment outcome in this 
cohort (Supplementary Figure 3). No other RAS was significantly as-
sociated with outcome within the whole cohort or within a specific 
genotype of patients.
4  |  DISCUSSION
This cohort represents both the largest reported cohort of patients 
retreated with SOF/VEL/VOX in the UK, and one of the largest 
cohorts of GT3- infected patients retreated with SOF/VEL/VOX. 
Our results show that retreatment of patients with SOF/VEL/VOX 
who have been failed by first- line therapy is very effective for GT1. 
However, patients with GT3 infection, cirrhosis or prior treatment 
with SOF/VEL or SOF +DCV have significantly lower SVR rates with 
SOF/VEL/VOX retreatment.
Our data shows that GT3- infected patients achieved lower SVR 
rates to SOF/VEL/VOX retreatment; the lowest SVR12 rates (42%) 
were observed in patients with GT3 infection, cirrhosis and prior 
SOF/VEL exposure. This is consistent with the data from Llaneras 
et al,13 which also showed a SVR rate of 81% for GT3- infected pa-
tients and 69% for GT3- infected patients with cirrhosis. However, 
Papaluca et al19 have shown an SVR rate of 90% in GT3 infected pa-
tients with cirrhosis. Belperio et al11 have shown that GT1- infected 
patients with prior SOF/VEL exposure had a reduced SVR rate of 
79% (15/19), yet a GT3- infected group with prior SOF/VEL exposure 
had a SVR rate of 85% (11/13) which is greater than the 75%(12/16) 
that was observed in our study but, these numbers remain small.
The overall prevalence of RAS was very high, but the presence 
of RAS in the NS3, NS5A or NS5B protein was not associated 
with SVR; this is in line with the analysis of RAS data from the 
POLARIS- 1 and 4 studies by Sarrzin et al.20 When RAS were an-
alysed separately the presence of the NS5A inhibitor RAS Y93H 
was significantly associated with treatment failure across the 
F I G U R E  2  Retreatment SVR12 rates 
for patients retreated with SOF/VEL/
VOX according to baseline and treatment 
characteristics for the whole cohort 
(n = 144). The SVR rate for each variable 
is shown with 95% confidence intervals 
shown. Daclatasvir (DCV), Sofosbuvir 
(SOF), Glecaprevir (GLE), Pibrentasvir 
(PIB), Grazoprevir (GZR), Elbasvir (EBR), 
Ledipasvir (LDV), Paritaprevir (PTV), 
Ombitasvir (OBV) Ritonavir (r), Dasabuvir 
(DAS), Velpatasvir (VEL)
129/144 18/22110/121 82/8647/58 126/1403/4 118/13011/14 120/1329/12
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whole cohort. However, when the genotype is included in the 
model used to test association, Y93H is no longer significantly 
associated with outcome. This data suggests that viral genotype 
is the more important viral factor for SOF/VEL/VOX retreatment 
outcome than the presence of RAS. PIB has been shown to be 
more effective than other NS5A inhibitors against viruses har-
bouring the Y93H RAS in- vitro.21 This suggests that GLE/PIB 
may be a more effective treatment for patients with the Y93H 
RAS. Thus, RAS testing to guide retreatment therapy could be 
an effective way to increase retreatment SVR rates. One of the 
limitations of this study is that the time between previous treat-
ment failure and pre- retreatment resequencing varied greatly in 
this cohort and in some cases was as long as 32 months. As RAS 
which have an effect on viral fitness tend to disappear over time, 
this study may underestimate the RAS present at previous DAA 
treatment failure.
At present SOF/VEL/VOX is the only recommended retreat-
ment regimen for patients previously failed by a NS5A inhibitor- 
containing regimen in England. These data suggest that whilst 
SOF/VEL/VOX may be a preferred regimen for non- GT3 infected 
patients, an alternative retreatment regimen for GT3- infected pa-
tients should also be considered, particularly those with cirrhosis 
and previous exposure to a DAA regimen containing SOF/VEL or 
SOF +DCV. Prior exposure to NS5A inhibitors can result in the 
F I G U R E  3  Univariate analysis of 
clinical factors associated with SVR for 
patients retreated with SOF/VEL/VOX 
according to baseline and treatment 
characteristics for the whole cohort 
(n = 144). The log odds ratio with 95% 
confidence intervals shown calculated 
using logistic regression. Values for 
which the SVR rate was 100% have not 
been included. Reference values used 
in regression when number of values 
is greater than two (ref), Daclatasvir 
(DCV), Sofosbuvir (SOF), Glecaprevir 
(GLE), Pibrentasvir (PIB), Grazoprevir 
(GZR), Elbasvir (EBR), Ledipasvir (LDV), 
Paritaprevir (PTV), Ombitasvir (OBV) 





























































No RAS 30% (43/144) 93% (40/43) NA NA NA
NS3 16% (23/144) 100% (23/23) .9 15.9 2062
NS5A 51% (74/144) 86% (64/74) .3 −0.7 0.8
NS5B 34% (49/144) 84% (41/49) .5 −0.5 0.96
NS3 + NS5A 8% (12/144) 100% (12/12) .9 15.9 1882
NS3 + NS5B 0% (0/144) NA NA NA NA
NS5A + NS5B 22% (31/144) 80% (25/31) .1 −1.1 0.75
NS3 + NS5A + NS5B 1% (1/144) 100% (1/1) .9 15.9 6522
Logistic regression was used to test the association between presence of RAS in the NS3, NS5A 
and NS5B proteins with SVR.
TA B L E  2  Prevalence of pre- 
retreatment RAS and SVR rates for 
patients retreated with SOF/VEL/VOX
1262  |    SMITH eT al.
emergence and long- term presence of RAS22,23 whereas the highly 
resistant SOF variant S282T in NS5B is rarely found after treat-
ment failure and, when detected, it is more transient.24,25 This 
would suggest that prior exposure to NS5A inhibitors in VEL/SOF 
and DCV +SOF regimens has a greater impact on retreatment. 
In addition to using SOF/VEL/VOX for 24 rather than 12 weeks 
or adding ribavirin,26 one current alternative to SOF/VEL/VOX 
for GT3 patients is off- label use of GLE/PIB +SOF +/- RBV. This 
combination was effective in a small retreatment trial27 and could 
represent an effective retreatment option for GT3 patients with 
prior exposure to SOF/VEL. Further retreatment options include 
adopting a resistance guided approach to treatment, increasing 
the SOF/VEL/VOX treatment duration or adding ribavirin. Where 
SOF/VEL/VOX retreatment has failed there are rescue therapy 
options. A recent study by Dietz J et al28 also showed that SOF/
VEL/VOX +/- RBV (Rescue SVR = 100% 4/4) and GLE/PIB +SOF +/- 
RBV (Rescue SVR = 79% 11/14) were effective rescue therapies in 
patients failed by SOF/VEL/VOX with GLE/PIB +/- RBV also being 
successfully used to retreat two patients.
In summary, our study shows that retreatment outcomes for 
patients failed by first- line DAA therapy are very successful for 
non- GT3- infected patients. However, for GT3- infected patients, 
particularly those with cirrhosis and failed by initial SOF/VEL treat-
ment, SVR rates were significantly lower and alternative retreatment 
regimens such as GLE/PIB +SOF should be considered.
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Protein RAS SVR Rate % (n) p log Odds ratio
Standard 
error
NS3 V55A 100 (4/4) .99 14.446 1199.772
K/Q80K 100 (14/14) .992 16.331 1638.472
K/Q80L 100 (2/2) .993 14.43 1696.734
Q80R 100 (1/1) .993 13.422 1455.398
A156T 100 (1/1) .993 13.422 1455.398
L175M 100 (1/1) .993 13.422 1455.398
NS5A M28T 100 (5/5) .993 15.454 1769.258
A30K 71 (10/14) .029 −1.465 0.67
K/R30K 100 (1/1) .993 13.422 1455.398
L/M31M 100 (2/2) .993 14.43 1696.734
L31M 100 (16/16) .992 16.373 1543.764
L31V 100 (3/3) .992 14.438 1385.378
H58D 100 (9/9) .99 15.183 1201.731
Y93C 100 (4/4) .99 14.446 1199.772
Y93H 78 (29/37) .014 −1.371 0.559
Y93N 100 (2/2) .993 14.43 1696.734
NS5B A/T/V150V 93 (26/28) .531 0.495 0.791
F/L159F 67 (2/3) .229 −1.512 1.257
L159F 100 (2/2) .993 14.43 1696.734
E/K206E 80 (16/20) .142 −0.943 0.642
E237G 100 (1/1) .993 13.422 1455.398
D/N244I 100 (1/1) .993 13.422 1455.398
C/N316H 100 (1/1) .993 13.422 1455.398
C/N316N 75 (3/4) .355 −1.099 1.189
I/V321I 50 (1/2) .125 −2.213 1.442
V321I 100 (1/1) .993 13.422 1455.398
Logistic regression was used to test the association between the presence of RAS with outcome in 
the whole cohort. Bold values indicates p<0.05.
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